Protalix BioTherapeutics (PLX) Total Current Liabilities (2010 - 2026)
Protalix BioTherapeutics' quarterly Total Current Liabilities came in at $27.4 million in Q1 2026, up 12.61% year-on-year from $24.3 million in Q1 2025, and up 3.28% quarter-over-quarter from $26.5 million in Q4 2025.
Protalix BioTherapeutics has reported Total Current Liabilities for 17 years, with the latest figure at $27.4 million in Q1 2026.
- For the quarter ending Q1 2026, Total Current Liabilities rose 12.61% year-over-year to $27.4 million; the trailing twelve-month figure through Mar 2026 stood at $27.4 million (up 12.61% YoY), and the FY2025 full-year result was $26.5 million, up 3.5% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $27.4 million, up from $26.5 million in the prior quarter.
- The five-year high for Total Current Liabilities was $58.0 million in Q2 2024, with the low at $21.9 million in Q3 2025.
- Average Total Current Liabilities over 5 years is $33.1 million, with a median of $31.0 million recorded in 2022.
- Year-over-year, Total Current Liabilities sank 67.83% in 2022 and surged 150.86% in 2024.
- Tracing PLX's Total Current Liabilities over 5 years: stood at $32.4 million in 2022, then surged by 40.4% to $45.5 million in 2023, then tumbled by 43.73% to $25.6 million in 2024, then grew by 3.5% to $26.5 million in 2025, then increased by 3.28% to $27.4 million in 2026.
- The last three Total Current Liabilities figures came in at $27.4 million (Q1 2026), $26.5 million (Q4 2025), and $21.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.70 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 636.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 66.94 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 13.42 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 3.88 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 5.11 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.35 Bn |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn | 27.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 27.39 Mn |
| Dec 31, 2025 | 26.52 Mn |
| Sep 30, 2025 | 21.95 Mn |
| Jun 30, 2025 | 24.09 Mn |
| Mar 31, 2025 | 24.32 Mn |
| Dec 31, 2024 | 25.62 Mn |
| Sep 30, 2024 | 24.22 Mn |
| Jun 30, 2024 | 57.97 Mn |
| Mar 31, 2024 | 54.83 Mn |
| Dec 31, 2023 | 45.53 Mn |
| Sep 30, 2023 | 43.36 Mn |
| Jun 30, 2023 | 23.11 Mn |
| Mar 31, 2023 | 31.52 Mn |
| Dec 31, 2022 | 32.43 Mn |
| Sep 30, 2022 | 34.30 Mn |
| Jun 30, 2022 | 30.96 Mn |
| Mar 31, 2022 | 35.33 Mn |
| Dec 31, 2021 | 33.18 Mn |
| Sep 30, 2021 | 42.76 Mn |
| Jun 30, 2021 | 96.25 Mn |
| Mar 31, 2021 | 80.86 Mn |
| Dec 31, 2020 | 86.47 Mn |
| Sep 30, 2020 | 43.90 Mn |
| Jun 30, 2020 | 42.42 Mn |
| Mar 31, 2020 | 47.63 Mn |
| Dec 31, 2019 | 40.18 Mn |
| Sep 30, 2019 | 33.32 Mn |
| Jun 30, 2019 | 25.99 Mn |
| Mar 31, 2019 | 27.04 Mn |
| Dec 31, 2018 | 25.35 Mn |
| Sep 30, 2018 | 24.34 Mn |
| Jun 30, 2018 | 18.49 Mn |
| Mar 31, 2018 | 24.15 Mn |
| Dec 31, 2017 | 22.75 Mn |
| Sep 30, 2017 | 26.59 Mn |
| Jun 30, 2017 | 19.12 Mn |
| Mar 31, 2017 | 20.29 Mn |
| Dec 31, 2016 | 66.21 Mn |
| Sep 30, 2016 | 10.33 Mn |
| Jun 30, 2016 | 11.46 Mn |
| Mar 31, 2016 | 9.28 Mn |
| Dec 31, 2015 | 11.24 Mn |
| Dec 31, 2014 | 64.35 Mn |
| Mar 31, 2014 | 26.78 Mn |
| Dec 31, 2013 | 26.70 Mn |
| Sep 30, 2013 | 25.23 Mn |
| Jun 30, 2013 | 26.63 Mn |
| Mar 31, 2013 | 24.41 Mn |
| Dec 31, 2012 | 25.76 Mn |
| Sep 30, 2012 | 20.44 Mn |
| Jun 30, 2012 | 21.33 Mn |
| Mar 31, 2012 | 17.72 Mn |
| Dec 31, 2011 | 18.69 Mn |
| Sep 30, 2011 | 18.31 Mn |
| Jun 30, 2011 | 20.28 Mn |
| Dec 31, 2010 | 18.90 Mn |